Right, the important thing is to have patents and then to do nothing to monetize them, other than wait on the FDA. My point actually was that XXII can be first in Europe and Asia, right now, with MRTP and we're doing nothing. And that we could have already been playing in the MJ space, and we're not.
The real difference in our beliefs is that you feel that if furthers the cause of shareholder value to be an enabler of Henry's less is more strategy and I don't. It has nothing to do with whether XXII is a viable plant technology company or not, it's about them getting off their collective rear ends.
Didn't Henry just get himself something like a 50% pay raise? At the same time share price has decreased by about that much during the past year? Nice work if you can get it.